# EDGAR Filing Document

**Accession Number:** 0001771910
**File Stem:** 0000950103-25-012566
**Filing Date:** 2025-9
**Character Count:** 30936
**Document Hash:** 44d297b42ec82bcd7120a2b04f1d04c2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950103-25-012566.hdr.sgml**: 20250930

**ACCESSION NUMBER**: 0000950103-25-012566

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20250930

**DATE AS OF CHANGE**: 20250930

**EFFECTIVENESS DATE**: 20250930

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ADC Therapeutics SA
- **CENTRAL INDEX KEY:** 0001771910
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** V8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-290616
- **FILM NUMBER:** 251360710

**BUSINESS ADDRESS:**
- **STREET 1:** BIOPOLE
- **STREET 2:** ROUTE DE LA CORNICHE 3B
- **CITY:** EPALINGES
- **STATE:** V8
- **ZIP:** 1066
- **BUSINESS PHONE:** 41 21 653 02 00

**MAIL ADDRESS:**
- **STREET 1:** BIOPOLE
- **STREET 2:** ROUTE DE LA CORNICHE 3B
- **CITY:** EPALINGES
- **STATE:** V8
- **ZIP:** 1066

**As filed with the Securities and Exchange Commission on September 30, 2025**

**Registration No. 333-__________**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT UNDER**

**THE SECURITIES ACT OF 1933**

**ADC THERAPEUTICS SA**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Switzerland** | **Not Applicable** |
| (State or other jurisdiction of<br> incorporation or organization) | (I.R.S. Employer<br> Identification No.) |

---

**Biopôle, Route de la Corniche 3B, 1066 Epalinges, Switzerland**

(Address of Principal Executive Offices)

**ADC Therapeutics SA Inducement Plan**

(Full title of the plans)

**ADC Therapeutics America, Inc.**

**430 Mountain Avenue, Suite 404**

**New Providence, NJ 07974**

(Name and Address of Agent For Service)

**(908) 731-5556**

(Telephone number, Including Area Code, of Agent For Service)

---

| |
|:---|
| ***Copies of all communications, including all communications sent to the agent for service, should be sent to:*** |
| **Deanna L. Kirkpatrick**<br> **Yasin Keshvargar**<br> **Davis Polk & Wardwell LLP**<br> **450 Lexington Avenue**<br> **New York, NY 10017**<br> **(212) 450-4000** |

---

**Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.**

---

| | |
|:---|:---|
| **Large accelerated filer □** | **Accelerated filer □** |
| **Non-accelerated filer ⌧** | **Smaller reporting company □** |
| **(Do not check if a smaller reporting company)** | **Emerging Growth Company □** |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. □

**REGISTRATION OF ADDITIONAL SHARES PURSUANT TO GENERAL INSTRUCTION E**

Pursuant to General Instruction E to Form S-8, the Registrant is filing this Registration Statement with the U.S. Securities and Exchange Commission (the "**Commission**") to register 1,000,000 additional common shares, par value CHF 0.08 per share, of the Registrant (the "**Common Shares**"), for issuance under the ADC Therapeutics SA Inducement Plan (the "**Inducement Plan**"). This Registration Statement hereby incorporates by reference the contents of the Registrant's registration statements on Form S-8 filed with the Commission on December 4, 2023 (File No. 333-275882) to the extent not superseded hereby.

**PART I**

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS**

The documents containing the information specified in Item 1 and Item 2 of Part I of Form S-8 will be sent or given to participants as specified by Rule 428(b)(1) under the Securities Act. In accordance with the rules and regulations of the Commission and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference.**

The following documents are incorporated herein by reference:

(a) The Registrant's Annual Report on Form 10-K filed with the Commission on March 27, 2025 (Registration No. 001-39071) (the "**Form 10-K**"), which contains the Registrant's audited financial statements for the latest fiscal year for which such statements have been filed;

(b) The Registrant's Quarterly Report on Form 10-Q filed with the Commission on August 12, 2025 (Registration No. 001-39071), which contains the Registrant's unaudited interim financial statements for the six months ended June 30, 2025 for which such statements have been filed;

(c) The Registrant's Quarterly Report on Form 10-Q filed with the Commission on May 14, 2025 (Registration No. 001-39071), which contains the Registrant's unaudited interim financial statements for the three months ended March 31, 2025 for which such statements have been filed;

(d) The Registrant's Current Reports on Form 8-K filed with the Commission on June 5, 2025 (Registration No. 001-39071) and June 12, 2025 (Registration No. 001-39071); and

(e) The description of the Registrant's share capital which is contained in the Registrant's Registration Statement Form 8-A (Registration No. 001-39071), dated May 11, 2020, as updated by Exhibit 4.1 to the Registrant's Form 10-K, including any amendments or supplements filed for the purpose of updating such description.

In addition, all documents subsequently filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the "**Exchange Act**"), prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, including any Reports of Foreign Private Issuers on Form 6-K submitted during such period (or portion thereof) that is identified in such form as being incorporated by reference into this Registration Statement, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents. The Registrant is not incorporating by reference any documents or portions thereof, whether specifically listed above or filed in the future, that are not deemed "filed" with the Commission.

Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein, (or in any other subsequently filed document which also is incorporated or deemed to be incorporated by reference herein), modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

**Item 8. Exhibits.**

---

| | |
|:---|:---|
| Exhibit Number |  |
| [4](http://www.sec.gov/Archives/edgar/data/1771910/000095010325007061/dp229762_0301.htm) | [ADC Therapeutics SA Amended and Restated Articles of Association (incorporated herein by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed with the Commission on June 5, 2025 (Registration No. 001-39071))](http://www.sec.gov/Archives/edgar/data/1771910/000095010325007061/dp229762_0301.htm) |
| [5](dp235208_ex5.htm) | [Opinion of Homburger AG, Swiss counsel of ADC Therapeutics SA, as to the validity of the common shares (filed herewith)](dp235208_ex5.htm) |
| [23.1](dp235208_ex5.htm) | [Consent of Homburger AG, Swiss counsel of ADC Therapeutics SA (included in Exhibit 5)](dp235208_ex5.htm) |
| [23.2](dp235208_ex2302.htm) | [Consent of PricewaterhouseCoopers SA, independent registered public accounting firm (filed herewith)](dp235208_ex2302.htm) |
| [24](#a_001) | [Powers of Attorney (included in the signature pages hereto)](#a_001) |
| [99.1](http://www.sec.gov/Archives/edgar/data/1771910/000095010323017156/dp203579_ex9902.htm) | [ADC Therapeutics SA Inducement Plan (incorporated herein by reference to Exhibit 99.2 to the Registrant's Form S-8 filed with the Commission on December 4, 2023 (File No. 333-275882))](http://www.sec.gov/Archives/edgar/data/1771910/000095010323017156/dp203579_ex9902.htm) |
| [99.2](dp235208_ex9902.htm) | [Amendment to the ADC Therapeutics SA Inducement Plan (filed herewith)](dp235208_ex9902.htm) |
| [107.1](dp235208_exfilingfees.htm) | [Filing fee table (filed herewith)](dp235208_exfilingfees.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing this Registration Statement and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Epalinges, Switzerland on September 30, 2025.

---

| | |
|:---|:---|
| ADC THERAPEUTICS SA | ADC THERAPEUTICS SA |
| By: | /s/ Ameet Mallik |
| Name: | Ameet Mallik |
| Title: | Chief Executive Officer |

---

**POWER OF ATTORNEY**

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Ameet Mallik, Jose "Pepe" Carmona and Peter J. Graham and each of them, individually, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, in connection with this registration statement, including to sign in the name and on behalf of the undersigned, this registration statement and any and all amendments thereto, including post-effective amendments and registrations filed pursuant to Rule 462 under the Securities Act, as amended, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto each such attorney-in-fact and agent full power and authority to do and perform each and every act in person, hereby ratifying and confirming all that each said attorney-in-fact and agent, or his or her substitutes, may lawfully do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **<u>Signature</u>** | **<u>Title</u>** | **<u>Date</u>** |
| /s/ Ameet Mallik | Chief Executive Officer and Director | September 30, 2025 |
| Ameet Mallik | (Principal Executive Officer) |  |
| /s/ Jose "Pepe" Carmona | Chief Financial Officer | September 30, 2025 |
| Jose "Pepe" Carmona | (Principal Financial Officer) |  |
| /s/ Lisa Källebo | Vice President, Corporate Controller and Chief Accounting Officer<br>| September 30, 2025 |
| Lisa Källebo | (Principal Accounting Officer) |  |
| /s/ Ron Squarer |  | September 30, 2025 |
| Ron Squarer | Chairman of the Board of Directors |  |
| /s/ Robert Azelby |  | September 30, 2025 |
| Robert Azelby | Director |  |
| /s/ Jean-Pierre Bizzari |  | September 30, 2025 |
| Jean-Pierre Bizzari | Director |  |
| /s/ Timothy Coughlin |  | September 30, 2025 |
| Timothy Coughlin | Director |  |
| /s/ Peter Hug |  | September 30, 2025 |
| Peter Hug | Director |  |
| /s/ Viviane Monges |  | September 30, 2025 |
| Viviane Monges | Director |  |
| /s/ Tyrell J. Rivers |  | September 30, 2025 |
| Tyrell J. Rivers | Director |  |
| /s/ Victor Sandor |  | September 30, 2025 |
| Victor Sandor | Director |  |
| /s/ Peter J. Graham |  | September 30, 2025 |
| Peter J. Graham | Chief Legal Officer, Authorized Representative in the United States |  |
| ADC Therapeutics America, Inc. |  |  |

---

## Exhibit 23.1

**EXHIBIT 5 and 23.1**

To: ADC Therapeutics SA Biopôle Route de la Corniche 3 B 1066 Epalinges Switzerland Homburger AG Prime Tower Hardstrasse 201 CH-8005 Zurich homburger.ch<br> T +41 43 222 10 00

September 30, 2025

**ADC Therapeutics SA – Registration Statement on Form S-8**

We, Homburger AG, have acted as special Swiss counsel to ADC Therapeutics SA, a stock corporation incorporated under the laws of Switzerland (the **Company**), in connection with the filing of a registration statement on Form S-8 (the **Registration Statement**), to be filed with the United States Securities and Exchange Commission (the **SEC**) on the date hereof for the purpose of registering under the United States Securities Act of 1933, as amended (the **Securities Act**), 1,000,000 common shares of the Company, each with a nominal value of CHF 0.08 (the **Common Shares**). As such counsel, we have been requested to give our opinion as to certain legal matters of Swiss law.

Capitalized terms used but not defined herein shall have the meaning ascribed to them in the Documents (as defined below).

I. Basis of Opinion

This opinion is confined to and given on the basis of the laws of Switzerland in force at the date hereof. Such laws and the interpretation thereof are subject to change. This opinion is also confined to the matters stated herein and the Documents (as defined below), and is not to be read as extending, by implication or otherwise, to any agreement or other document referred to in any of the Documents or any other matter.

For purposes of this opinion, we have not conducted any due diligence or similar investigation as to (i) factual circumstances that are or may be referred to in the Documents or (ii) the assets subject to the Documents, and we express no opinion as to the accuracy of representations and warranties of facts set out in the Documents or the factual background assumed therein.

1/6

For purposes of this opinion, we have only reviewed the following documents (collectively, the **Documents**):

&nbsp;&nbsp;&nbsp;&nbsp;(i) an electronic copy of the Registration Statement;

&nbsp;&nbsp;&nbsp;&nbsp;(ii) an electronic copy of the Company's inducement plan effective
as of December 1, 2023 (the **Inducement Plan**);

&nbsp;&nbsp;&nbsp;&nbsp;(iii) an electronic copy of the amendment No. 1 to the Inducement
Plan dated September 25, 2025 (the **Amendment**, and together with the Inducement Plan, the **Plan**);

&nbsp;&nbsp;&nbsp;&nbsp;(iv) an electronic copy of a written resolution of the board of
directors of the Company, dated December 1, 2023, approving, *inter alia*, the Inducement Plan (the **Inducement Plan Board Resolution**);

&nbsp;&nbsp;&nbsp;&nbsp;(v) an electronic copy of a written resolution of the board of
directors of the Company, dated September 25, 2025, approving, *inter alia*, the Amendment (the **Amendment Board Resolution**,
and together with the Inducement Plan Resolution, the **Board Resolutions**);

&nbsp;&nbsp;&nbsp;&nbsp;(vi) an electronic copy of the notarized articles of association
(*statuts*) of the Company dated June 12, 2025 (the **Articles of Association**), containing, *inter alia*, a capital range
from CHF 8,144,884.08 (lower limit) to CHF 12,123,038.40 (upper limit), authorizing the board of directors of the Company to issue up
to 36,695,768 fully paid up common shares with a nominal value of CHF 0.08 each (the **Capital Range**), and (ii) a separate conditional
share capital (*capital conditionnel*) for employee participation providing for the issuance of up to 12,776,259 fully paid up common
shares with a nominal value of CHF 0.08 (the **Conditional Share Capital**); and

&nbsp;&nbsp;&nbsp;&nbsp;(vii) an electronic copy of a certified excerpt from the Commercial
Register of the Canton of Vaud, Switzerland, dated September 24, 2025, relating to the Company (the **Excerpt**).

No documents have been reviewed by us in connection with this opinion other than the Documents. Accordingly, we shall limit our opinion to the Documents and their legal implications under Swiss law.

In this opinion, Swiss legal concepts are expressed in English terms and not in their original language. These concepts may not be identical to the concepts described by the same English terms as they exist under the laws of other jurisdictions. With respect to Documents governed by laws other than the laws of Switzerland, for purposes of this opinion we have relied on the plain meaning of the words and expressions contained therein without regard to any import they may have under the relevant governing law.

II. Assumptions

2/6

In rendering the opinions below, we have assumed the following:

&nbsp;&nbsp;&nbsp;&nbsp;(a) all documents produced to us as originals are authentic and
complete, and all documents produced to us as copies (including, without limitation, electronic copies) conform to the original;

&nbsp;&nbsp;&nbsp;&nbsp;(b) all documents produced to us as originals and the originals
of all documents produced to us as copies were duly executed and certified, as applicable, by the individuals purported to have executed
or certified, as the case may be, such documents, and any electronic signatures on any such document have been affixed thereto by the
individual to whom such electronic signature belongs and such individual has saved and submitted such document as so electronically signed
in such a manner so as to prevent removal or other alteration of such signature;

&nbsp;&nbsp;&nbsp;&nbsp;(c) all signatures appearing on all original documents or copies
thereof which we have examined are genuine;

&nbsp;&nbsp;&nbsp;&nbsp;(d) each party to the Documents is a corporation or other legal
entity duly organized and validly existing and in good standing (if applicable) under the laws of the jurisdiction of its incorporation
and/or establishment and none of the parties to the Documents (other than the Company) has passed or, until the issuance of all Common
Shares, will have passed a voluntary winding-up resolution; no petition has been, or, until the issuance of all Common Shares, will be
presented or order made by a court for the winding-up, dissolution, bankruptcy or administration of any party (other than the Company);
and no receiver, trustee in bankruptcy, administrator or similar officer has been or, until the issuance of all Common Shares, will have
been appointed in relation to any of the parties (other than the Company) or any of their assets or revenues;

&nbsp;&nbsp;&nbsp;&nbsp;(e) except as expressly opined upon herein, and to the extent
relevant for purposes of this opinion, all information and confirmations contained in the Documents, and all material statements made
to us in connection with the Documents, are true and accurate;

&nbsp;&nbsp;&nbsp;&nbsp;(f) there are no provisions of the laws of any jurisdiction other
than Switzerland that may affect the opinions expressed herein;

&nbsp;&nbsp;&nbsp;&nbsp;(g) the Registration Statement has been duly filed by the Company;

&nbsp;&nbsp;&nbsp;&nbsp;(h) the filing of the Registration Statement with the SEC has
been authorized by all necessary actions under all applicable laws other than Swiss law;

&nbsp;&nbsp;&nbsp;&nbsp;(i) the Registration Statement, the Excerpt and the Articles
of Association are unchanged, correct, complete and up-to-date and in full force and effect as of the date hereof and no changes have
been made which should have been or should be reflected in the Registration Statement, the Excerpt or the Articles of Association, as
the case may be, as of the date hereof;

&nbsp;&nbsp;&nbsp;&nbsp;(j) the Board Resolutions (i) have been duly resolved in
the manner set forth therein, (ii) have not been amended, and (iii) are in full force and effect;

3/6

&nbsp;&nbsp;&nbsp;&nbsp;(k) the Plan has not been amended and is in full force and effect;

&nbsp;&nbsp;&nbsp;&nbsp;(l) prior to the issuance of any Common Shares, the board of
directors of the Company will have duly authorized the issuance of any Common Shares or rights to receive Common Shares and will have
validly excluded the pre-emptive rights of the existing shareholders for purposes of the offering of Common Shares under the Plan as
contemplated in the Registration Statement, and such authorization and exclusion will not have been amended and will be in full force
and effect until the issuance of all Common Shares;

&nbsp;&nbsp;&nbsp;&nbsp;(m) any Common Shares issued out of the Capital Range and/or
the Conditional Share Capital will be listed on the New York Stock Exchange in accordance with applicable laws and regulations;

&nbsp;&nbsp;&nbsp;&nbsp;(n) all notices by which a right to receive Common Shares issued
out of the Capital Range and/or the Conditional Share Capital is exercised will be duly delivered in accordance with Swiss law, the Plan
and any applicable contractual arrangements;

&nbsp;&nbsp;&nbsp;&nbsp;(o) to the extent the Company issues Common Shares out of the
Capital Range and/or the Conditional Share Capital against cash, the performance of the contribution in money shall be made at a banking
institution subject to the Swiss Federal Act on Banks and Savings Banks of November 8, 1934, as amended;

&nbsp;&nbsp;&nbsp;&nbsp;(p) the Company has not entered and will not enter into any transaction
which could be construed as repayment of share capital (*restitution des versements*); and

&nbsp;&nbsp;&nbsp;&nbsp;(q) all authorizations, approvals, consents, licenses, exemptions,
other than as required by mandatory Swiss law applicable to the Company or the Articles of Association, and other requirements for the
filing of the Registration Statement or for any other activities carried on in view of, or in connection with, the performance of the
obligations expressed to be undertaken by the Company in the Registration Statement have been duly obtained or fulfilled in due time
and are and will remain in full force and effect, and any related conditions to which the parties thereto are subject have been satisfied.

III. Opinion

Based on the foregoing and subject to the qualifications set out below, we are of the opinion that:

&nbsp;&nbsp;&nbsp;&nbsp;1. The Company is a corporation (*société anonyme*)
duly incorporated and validly existing under the laws of Switzerland with all requisite corporate power and authority to enter into,
to perform and to conduct its business as described in the Articles of Association.

&nbsp;&nbsp;&nbsp;&nbsp;2. The Common Shares that may be issued from the Capital Range
and/or the Conditional Share Capital, if and when such Common Shares are issued pursuant to the Articles of Association, the Plan, any
applicable contractual arrangements and Swiss law, and after the subscription amount for such Common Shares has been paid-in in cash
or by way of set-off, and when such Common Shares have been entered into the Company's book of uncertificated securities, will be validly
issued, fully paid as to their nominal value and non-assessable.

4/6

IV. Qualifications

The above opinions are subject to the following qualifications:

&nbsp;&nbsp;&nbsp;&nbsp;(a) The lawyers of our firm are members of the Zurich bar and
do not hold themselves out to be experts in any laws other than the laws of Switzerland. Accordingly, we are opining herein as to Swiss
law only, based on our independent professional judgment, and we express no opinion with respect to the applicability or the effect of
the laws of any other jurisdiction to or on the matters covered herein.

&nbsp;&nbsp;&nbsp;&nbsp;(b) The exercise of voting rights and rights related thereto
with respect to any Common Shares is only permissible if and when such Common Shares have been validly issued and in any case after registration
in the Company's share register as a shareholder with voting rights in accordance with the provisions of, and subject to the limitations
provided in, the Articles of Association.

&nbsp;&nbsp;&nbsp;&nbsp;(c) We have not investigated or verified the truth or accuracy
of the information contained in the Registration Statement, nor have we been responsible for ensuring that no material information has
been omitted from it.

&nbsp;&nbsp;&nbsp;&nbsp;(d) We express no opinion as to tax, banking, insurance or regulatory
matters or as to any commercial, accounting, calculating, auditing or other non-legal matter.

\* \* \*

We have issued this opinion as of the date hereof and we assume no obligation to advise you of any changes in fact or in law that are made or brought to our attention hereafter.

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act.

This opinion is governed by and shall be construed in accordance with the laws of Switzerland. We confirm our understanding that all disputes arising out of or in connection with this opinion shall be subject to the exclusive jurisdiction of the courts of the Canton of Zurich, Switzerland, venue being the City of Zurich.

[*Signature page follows*]

5/6

Sincerely yours

Homburger AG

6/6

## Exhibit 23.2

**EXHIBIT 23.2**

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of ADC Therapeutics SA of our report dated March 27, 2025 relating to the financial statements, which appears in ADC Therapeutics SA's Annual Report on Form 10-K for the year ended December 31, 2024.

/s/ PricewaterhouseCoopers SA

Lausanne, Switzerland

September 30, 2025

## Exhibit 99.2

**EXHIBIT 99.2**

**AMENDMENT NO. 1 TO ADC THERAPEUTICS SA INDUCEMENT PLAN**

**Effective Date: September 25, 2025**

WHEREAS, ADC Therapeutics SA (the "**Company**") has adopted the ADC Therapeutics SA Inducement Plan, effective as of December 1, 2023 (the "**Plan**"); and

WHEREAS, the Company wishes to amend the Plan to increase the number of common shares of the Company, par value CHF 0.08 per share, available for issuance under the Plan.

NOW, THEREFORE, the Plan shall be amended, effective as the date hereof, as follows:

1. Section 4(a) of the Plan is hereby amended and restated in its entirety to read as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Subject to adjustment as provided in ‎Section 4(c), the maximum number of Shares available for issuance under the Plan shall not exceed 2,000,000 Shares. Share subject to an Award under the Plan shall be for an Award granted as an inducement grant pursuant to New York Stock Exchange Listed Company Manual 303A.08 or under the rules of an exchange on which the Shares are traded, to the extent the Shares are not traded on the New York Stock Exchange.

2. Section 4(d) of the Plan is hereby amended and restated in its entirety to read as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Any Shares delivered pursuant to an Award may consist, in whole or in part, of Shares issued out of the Company's capital range, the Company's conditional capital for employee participation, or Shares acquired by the Company and/or held as treasury shares. In its sole discretion, the Company or any of its Subsidiaries or any person appointed by any of them may, in its own name or in the name of a Participant and on behalf of a Participant, subscribe to Shares, pay in the issue price and do any other action to create the Shares or direct the Participant to do so. Any Shares delivered pursuant to an Award shall be issued as fully paid shares, and the exercise price and/or subscription price per Share pursuant to any Award, if applicable, shall always be at least equal to or greater than the par value per Share. A Participant shall not have any rights as a shareholder of the Company (including as to voting and dividends) until Shares are actually settled and delivered to the Participant and upon entry of the Participant into the share register of the Company as shareholder of such Shares with voting rights.

Except as expressly set forth in this Amendment No. 1, all other terms and conditions set forth in the Plan shall remain in full force and effect. Each capitalized term used and not defined herein shall have the meaning set forth in the Plan.

## Ex-Filing

?xml version='1.0' encoding='ASCII'? Filing Fee Exhibit

**Ex-Filing Fees**

**CALCULATION OF FILING FEE TABLES**

**S-8**

**ADC THERAPEUTICS SA**

**Table 1: Newly Registered Securities**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security Type** | **Security Class Title** | **Notes** | **Fee Calculation<br> Rule** | **Amount Registered** | **Proposed Maximum Offering<br> Price Per Unit** | **Maximum Aggregate Offering Price** | **Fee Rate** | **Amount of Registration Fee** |
| Equity | Common Shares, par value CHF 0.08 | (1) | Other | 1000000 | $3.44 | $3440000.00 | 0.0001531 | $526.67 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | $3440000.00 |  | 526.67 |
| Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: |  |  | 0.00 |
| Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: |  |  | $526.67 |

---

**__________________________________________ Offering Note(s)**

&nbsp;&nbsp;&nbsp;&nbsp;(1) This Registration
 Statement on Form S-8 (this "**Registration Statement**") covers common shares, par value CHF 0.08 each ()"**Common Shares** "), of ADC Therapeutics SA (the "**Registrant**") issuable pursuant to the ADC Therapeutics SA Inducement
 Plan, as amended (the "**Inducement Plan** "). Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the
 "Securities Act"), this Registration Statement shall also cover any additional Common Shares that become issuable under
 the Inducement Plan by reason of any share dividend, share split or other similar transaction. The proposed maximum offering
 price per unit has been computed solely for the purpose of calculating the registration fee pursuant to Rule 457(c) and 457(h) under
 the Securities Act on the basis of the average of the high and low prices per share of Ordinary Shares on the New York Stock Exchange
 on September 25, 2025, which date is within five business days prior to filing this Registration Statement.